360 related articles for article (PubMed ID: 16098464)
41. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
42. Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase.
Harada K; Hiramoto-Yamaki N; Negishi M; Katoh H
Exp Cell Res; 2011 Jul; 317(12):1701-13. PubMed ID: 21621533
[TBL] [Abstract][Full Text] [Related]
43. Raf kinase inhibitor protein regulation of raf and MAPK signaling.
Hagan S; Garcia R; Dhillon A; Kolch W
Methods Enzymol; 2006; 407():248-59. PubMed ID: 16757329
[TBL] [Abstract][Full Text] [Related]
44. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
45. Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells.
Nur-E-Kamal A; Zhang A; Keenan SM; Wang XI; Seraj J; Satoh T; Meiners S; Welsh WJ
Mol Cancer Res; 2005 May; 3(5):297-305. PubMed ID: 15886301
[TBL] [Abstract][Full Text] [Related]
46. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
47. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
Weng MS; Ho CT; Ho YS; Lin JK
Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
[TBL] [Abstract][Full Text] [Related]
48. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
49. Differential EphA2 epitope display on normal versus malignant cells.
Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS
Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720
[TBL] [Abstract][Full Text] [Related]
50. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A
Oncogene; 2006 Feb; 25(6):877-87. PubMed ID: 16170339
[TBL] [Abstract][Full Text] [Related]
51. LMW-PTP is a positive regulator of tumor onset and growth.
Chiarugi P; Taddei ML; Schiavone N; Papucci L; Giannoni E; Fiaschi T; Capaccioli S; Raugei G; Ramponi G
Oncogene; 2004 May; 23(22):3905-14. PubMed ID: 15021900
[TBL] [Abstract][Full Text] [Related]
52. Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli.
Zabell KM; Laurence JS; Kinch MS; Knapp DW; Stauffacher CV
Protein Expr Purif; 2006 May; 47(1):210-6. PubMed ID: 16426859
[TBL] [Abstract][Full Text] [Related]
53. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
54. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
55. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
56. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway.
Fritsche-Guenther R; Noske A; Ungethüm U; Kuban RJ; Schlag PM; Tunn PU; Karle J; Krenn V; Dietel M; Sers C
Histopathology; 2010 Dec; 57(6):836-50. PubMed ID: 21166698
[TBL] [Abstract][Full Text] [Related]
57. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
Xu Q; Lin WC; Petit RS; Groves JT
Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062
[TBL] [Abstract][Full Text] [Related]
58. Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling.
Gao Z; Han X; Zhu Y; Zhang H; Tian R; Wang Z; Cui Y; Wang Z; Niu R; Zhang F
Cell Death Dis; 2021 Apr; 12(5):414. PubMed ID: 33879771
[TBL] [Abstract][Full Text] [Related]
59. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
60. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.
Lin S; Gordon K; Kaplan N; Getsios S
Mol Biol Cell; 2010 Nov; 21(22):3902-14. PubMed ID: 20861311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
